Dr. Goff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
177 Fort Washington Ave
MHB 7GS 313
New York, NY 10032Phone+1 813-787-4286
Education & Training
- Brigham and Women's HospitalFellowship, Complex General Surgical Oncology, 2012 - 2014
- Massachusetts General HospitalFellowship, Complex General Surgical Oncology, 2012 - 2014
- New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 2009 - 2012
- National Cancer InstituteFellowship, Tumor Immunology, 2005 - 2009
- New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Surgery, 2003 - 2005
- University of South Florida College of MedicineClass of 2003
Certifications & Licensure
- NY State Medical License 2005 - 2025
- MA State Medical License 2012 - 2018
- American Board of Surgery Surgery
Publications & Presentations
PubMed
- 4 citationsAdoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.Maria Parkhurst, Stephanie L Goff, Frank J Lowery, Rachel K Beyer, Hyunmi Halas
Nature Medicine. 2024-09-01 - 1 citationsNeoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.Noam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Zhiya Yu
Journal for Immunotherapy of Cancer. 2024-05-30 - 4 citationsRapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.Lekha Mikkilineni, Danielle A Natrakul, Norris Lam, Elisabet E Manasanch, Jennifer Mann
Molecular Therapy. 2024-02-07
Press Mentions
- Understanding the Risk of Second Cancers After CAR T-cell TherapyAugust 13th, 2024
- Evidence Mounting for TILs as Possible First-Line Cancer TherapySeptember 24th, 2021
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes May Be Less Effective in Patients with Pretreated Metastatic MelanomaAugust 18th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: